Developer docs
API playgroundTry for free, no card

Search company profiles

PSI CRO AG

Full company profile

uuid0007c55

Namestring
PSI CRO AG
Legal namestring
PSI CRO AG
Websiteurl
psi-cro.com
Company typeenum
Private
Founded yearint
1995
Descriptiontext

PSI CRO AG is a global full-service contract research organization (CRO) founded in 1995 and headquartered in Zug, Switzerland. The company provides end-to-end clinical development services — including protocol design, site management, data management, biostatistics, regulatory affairs, medical monitoring, and pharmacovigilance — to pharmaceutical and biotechnology sponsors, with documented specializations across oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory therapeutics. Its customer base includes Top 20 global pharmaceutical companies and clinical-stage biotech sponsors such as Melinta Therapeutics and Atossa Therapeutics.

The company's core differentiator is the proprietary INTELIA™ platform, which integrates six operational modules: SYNETIC™ (AI-powered semantic knowledge platform for site intelligence, launched January 2026 and built on data from 500,000+ institutions and 3 million study sites); VISIONAL™ (clinical and financial feasibility modeling with GenAI); CLARITY™ (budgeting); CADENCE™ (budget tracking); INSITE™ (investigator grant calculation); and PACE™ (risk-based monitoring). SYNETIC™ employs agentic AI, NLP, knowledge graphs, and multimodal semantic data platforms (OmniRAG architecture) for predictive site selection. PSI CRO AG operates across 58 countries with 3,200+ professionals and reports on-time delivery above 90% on its projects.

PSI CRO AG generates revenue through professional-services contracts with pharmaceutical and biotech sponsors on a quote-based, project-specific model. Pricing is not publicly disclosed and is tailored to study complexity, therapeutic area, and geographic scope. The company employs a direct enterprise field sales motion, with RFP-driven engagement and no third-party distribution. PSI CRO AG is privately held by its founding management group — described in the input as the only fully independent and privately owned global mid-sized CRO — with no disclosed external funding rounds, parent company, or institutional investors.

Short descriptiontext

PSI CRO AG is a privately held, globally operating full-service contract research organization delivering pivotal Phase 2/3 clinical trials across 58 countries for pharmaceutical and biotech sponsors, supported by its proprietary INTELIA™ AI-powered platform suite.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices24 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, clinical trial management, pharmaceutical drug development, biotech clinical trials
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

PSI CRO AG generates revenue through project-based professional services contracts with pharmaceutical and biotech sponsors, providing full-service CRO services across clinical development. Contracts are typically long-term, multi-study engagements with defined project milestones and deliverables.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1SYNETIC™
Description

AI-powered semantic knowledge platform for clinical trial site intelligence, selection, and startup acceleration

psi-cro.com
+6 more records
Core offering1 text field

PSI CRO AG is a global full-service Contract Research Organization (CRO) that delivers pivotal Phase II–III clinical trials on time for pharmaceutical and biotech sponsors across eight therapeutic areas: oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory. Operations span 58 countries with 3,200+ professionals and 10,000+ investigator sites, supported by the proprietary INTELIA™ AI-powered technology platform suite (SYNETIC™, VISIONAL™, CLARITY™, CADENCE™, INSITE™, PACE™).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 90%+ of projects delivered on schedule
Product overview1 text field

PSI CRO AG is a global full-service contract research organization (CRO) that operates as a single unified offering with proprietary technology platforms. The core service is the delivery of pivotal Phase 2/3 clinical trials on-time, supported by the INTELIA™ technology platform comprising six integrated modules: SYNETIC™ (AI-powered site intelligence), VISIONAL™ (clinical/financial feasibility), CLARITY™ (budgeting), CADENCE™ (budget tracking), INSITE™ (investigator grants), and PACE™ (monitoring planning). CRO services span oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory therapeutics across 58 countries.

Product and service11 records
1INTELIA™ Clinical Trial Intelligence Platform
CategoryClinical Trial Intelligence Platform
Description

Integrated AI-powered clinical trial intelligence platform suite combining SYNETIC™, VISIONAL™, CLARITY™, CADENCE™, INSITE™, and PACE™ modules to optimize trial planning, feasibility, budgeting, tracking, site grants, and monitoring for pharmaceutical and biotech sponsors.

2SYNETIC™ AI-Powered Semantic Site Intelligence Platform
CategoryAI-Powered Site Intelligence Platform
Description

Standalone AI-powered semantic knowledge platform for clinical trial site intelligence, selection, and startup acceleration, built on data from 500,000+ institutions, 3 million study sites, and 300,000 clinical projects with agentic AI, NLP, knowledge graphs, and predictive analytics.

3VISIONAL™ Clinical and Financial Feasibility Platform
CategoryFeasibility Analysis Platform
Description

AI/ML-driven platform combining clinical and financial feasibility to model and compare hundreds of enrollment scenarios, budgets, and probability of success for protocols and portfolios, with live budget simulations.

4Oncology CRO Services
CategoryTherapeutic Area CRO Service
Description

Full-service oncology clinical research organization support for pivotal Phase 2/3 trials, including 60 board-certified oncologists, expertise in radiopharmaceuticals, ADCs, and cell therapies, and access to 10,000 sites in 62 countries.

5Gastroenterology (GI) CRO Services
CategoryTherapeutic Area CRO Service
Description

Specialized GI and IBD clinical trial services with 6,000 GI sites in 60 countries, 50%+ higher enrollment rates, in-house board-certified gastroenterologists, and expertise in complex combination and platform studies.

6Hematology CRO Services
CategoryTherapeutic Area CRO Service
Description

Hematology and hematology-oncology clinical trial services with 4,200 hematology sites in 60 countries, 93% on-time enrollment rate, 14 drug approvals including one of the first gene therapies, and 10 in-house hematologists.

7Cell and Gene Therapy CRO Services
CategoryTherapeutic Area CRO Service
Description

Advanced therapy clinical trial support with 20 years of CGT experience, expertise across CAR-T, gene editing, and stem cell therapy, involvement in key industry approvals, and specialized site support including cell therapy nurses and technology specialists.

8Neurology CRO Services
CategoryTherapeutic Area CRO Service
Description

CNS and neuroscience clinical trial services with 10 CNS drug approvals, 75% of MS drug approvals in the past 5 years, 20+ years of CNS experience, expertise in adult and pediatric populations, and dedicated support for emerging technologies including neuroimaging.

9Infectious Diseases CRO Services
CategoryTherapeutic Area CRO Service
Description

Infectious disease clinical trial services having delivered 50% of antibiotics to market since 2010, with 14 drug approvals, 28,000 patients enrolled across 45 countries, and ID-focused laboratory support services.

10Radiopharmaceuticals CRO Services
CategoryTherapeutic Area CRO Service
Description

Leading radiopharmaceutical clinical trial services with #1 industry theranostic approval, 40% of pivotal RLT studies, 1,000+ qualified RLT sites, and a dedicated radiopharmaceutical strategy team including nuclear medicine, imaging, dosimetry, and nuclear pharmacy experts.

11Respiratory CRO Services
CategoryTherapeutic Area CRO Service
Description

Respiratory and pulmonary clinical trial services with 6 drug approvals, 10,000+ patients enrolled, 50+ late-stage respiratory studies, and expertise in COPD, IPF, asthma, pneumonia, and specialized spirometry standardization.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

PSI CRO AG discussed site ID collaboration with Sanofi at SCOPE 2026, indicating a co-development partnership for clinical site identification and activation services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PSI CRO AG collaborates with the University of Missouri on radiopharmaceutical clinical research, leveraging academic expertise and patient populations for specialized oncology studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PSI CRO AG partners with Xcancer in the field of radiopharmaceuticals, combining Xcancer's specialized oncology expertise with PSI CRO AG's global operational capabilities for clinical development.

Strategic tierCoreTypeTechnology or Integration
Description

PSI CRO AG utilizes its VISIONAL platform in collaboration with ITM Isotope Technologies Munich SE for clinical and financial feasibility assessment in radiopharmaceutical studies, integrating PSI CRO AG's technology with ITM's isotope expertise.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PSI CRO AG

Contract Research Servicespsi-cro.com

PSI CRO AG is a privately held, globally operating full-service contract research organization delivering pivotal Phase 2/3 clinical trials across 58 countries for pharmaceutical and biotech sponsors, supported by its proprietary INTELIA™ AI-powered platform suite.

What PSI CRO AG does

PSI CRO AG is a global full-service contract research organization (CRO) founded in 1995 and headquartered in Zug, Switzerland. The company provides end-to-end clinical development services — including protocol design, site management, data management, biostatistics, regulatory affairs, medical monitoring, and pharmacovigilance — to pharmaceutical and biotechnology sponsors, with documented specializations across oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory therapeutics. Its customer base includes Top 20 global pharmaceutical companies and clinical-stage biotech sponsors such as Melinta Therapeutics and Atossa Therapeutics.

The company's core differentiator is the proprietary INTELIA™ platform, which integrates six operational modules: SYNETIC™ (AI-powered semantic knowledge platform for site intelligence, launched January 2026 and built on data from 500,000+ institutions and 3 million study sites); VISIONAL™ (clinical and financial feasibility modeling with GenAI); CLARITY™ (budgeting); CADENCE™ (budget tracking); INSITE™ (investigator grant calculation); and PACE™ (risk-based monitoring). SYNETIC™ employs agentic AI, NLP, knowledge graphs, and multimodal semantic data platforms (OmniRAG architecture) for predictive site selection. PSI CRO AG operates across 58 countries with 3,200+ professionals and reports on-time delivery above 90% on its projects.

PSI CRO AG generates revenue through professional-services contracts with pharmaceutical and biotech sponsors on a quote-based, project-specific model. Pricing is not publicly disclosed and is tailored to study complexity, therapeutic area, and geographic scope. The company employs a direct enterprise field sales motion, with RFP-driven engagement and no third-party distribution. PSI CRO AG is privately held by its founding management group — described in the input as the only fully independent and privately owned global mid-sized CRO — with no disclosed external funding rounds, parent company, or institutional investors.

PSI CRO AG firmographics

Firmographics
Name
PSI CRO AG
Legal name
PSI CRO AG
Website
https://psi-cro.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
PSI CRO AG is a privately held, globally operating full-service contract research organization delivering pivotal Phase 2/3 clinical trials across 58 countries for pharmaceutical and biotech sponsors, supported by its proprietary INTELIA™ AI-powered platform suite.
Ownership category
akta.pro rank

PSI CRO AG industry classification

Industry
Product category
Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Clinical research services
  • Contract research organization
  • Clinical trial management
  • Pharmaceutical drug development
  • Biotech clinical trials

Where PSI CRO AG is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices24 records

Markets served

PSI CRO AG business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: PSI CRO AG generates revenue through project-based professional services contracts with pharmaceutical and biotech sponsors, providing full-service CRO services across clinical development. Contracts are typically long-term, multi-study engagements with defined project milestones and deliverables.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

PSI CRO AG product offering

Product offering

Core offering

PSI CRO AG is a global full-service Contract Research Organization (CRO) that delivers pivotal Phase II–III clinical trials on time for pharmaceutical and biotech sponsors across eight therapeutic areas: oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory. Operations span 58 countries with 3,200+ professionals and 10,000+ investigator sites, supported by the proprietary INTELIA™ AI-powered technology platform suite (SYNETIC™, VISIONAL™, CLARITY™, CADENCE™, INSITE™, PACE™).

Product overview

PSI CRO AG is a global full-service contract research organization (CRO) that operates as a single unified offering with proprietary technology platforms. The core service is the delivery of pivotal Phase 2/3 clinical trials on-time, supported by the INTELIA™ technology platform comprising six integrated modules: SYNETIC™ (AI-powered site intelligence), VISIONAL™ (clinical/financial feasibility), CLARITY™ (budgeting), CADENCE™ (budget tracking), INSITE™ (investigator grants), and PACE™ (monitoring planning). CRO services span oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory therapeutics across 58 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • SYNETIC™: AI-powered semantic knowledge platform for clinical trial site intelligence, selection, and startup acceleration
  • VISIONAL™
  • INTELIA™
  • CLARITY™
  • CADENCE™
  • INSITE™
  • PACE™

Products and services

  • INTELIA™ Clinical Trial Intelligence Platform Integrated AI-powered clinical trial intelligence platform suite combining SYNETIC™, VISIONAL™, CLARITY™, CADENCE™, INSITE™, and PACE™ modules to optimize trial planning, feasibility, budgeting, tracking, site grants, and monitoring for pharmaceutical and biotech sponsors.
  • SYNETIC™ AI-Powered Semantic Site Intelligence Platform Standalone AI-powered semantic knowledge platform for clinical trial site intelligence, selection, and startup acceleration, built on data from 500,000+ institutions, 3 million study sites, and 300,000 clinical projects with agentic AI, NLP, knowledge graphs, and predictive analytics.
  • VISIONAL™ Clinical and Financial Feasibility Platform AI/ML-driven platform combining clinical and financial feasibility to model and compare hundreds of enrollment scenarios, budgets, and probability of success for protocols and portfolios, with live budget simulations.
  • Oncology CRO Services Full-service oncology clinical research organization support for pivotal Phase 2/3 trials, including 60 board-certified oncologists, expertise in radiopharmaceuticals, ADCs, and cell therapies, and access to 10,000 sites in 62 countries.
  • Gastroenterology (GI) CRO Services Specialized GI and IBD clinical trial services with 6,000 GI sites in 60 countries, 50%+ higher enrollment rates, in-house board-certified gastroenterologists, and expertise in complex combination and platform studies.
  • Hematology CRO Services Hematology and hematology-oncology clinical trial services with 4,200 hematology sites in 60 countries, 93% on-time enrollment rate, 14 drug approvals including one of the first gene therapies, and 10 in-house hematologists.
  • Cell and Gene Therapy CRO Services Advanced therapy clinical trial support with 20 years of CGT experience, expertise across CAR-T, gene editing, and stem cell therapy, involvement in key industry approvals, and specialized site support including cell therapy nurses and technology specialists.
  • Neurology CRO Services CNS and neuroscience clinical trial services with 10 CNS drug approvals, 75% of MS drug approvals in the past 5 years, 20+ years of CNS experience, expertise in adult and pediatric populations, and dedicated support for emerging technologies including neuroimaging.
  • Infectious Diseases CRO Services Infectious disease clinical trial services having delivered 50% of antibiotics to market since 2010, with 14 drug approvals, 28,000 patients enrolled across 45 countries, and ID-focused laboratory support services.
  • Radiopharmaceuticals CRO Services Leading radiopharmaceutical clinical trial services with #1 industry theranostic approval, 40% of pivotal RLT studies, 1,000+ qualified RLT sites, and a dedicated radiopharmaceutical strategy team including nuclear medicine, imaging, dosimetry, and nuclear pharmacy experts.
  • Respiratory CRO Services Respiratory and pulmonary clinical trial services with 6 drug approvals, 10,000+ patients enrolled, 50+ late-stage respiratory studies, and expertise in COPD, IPF, asthma, pneumonia, and specialized spirometry standardization.

Quantifiable outcome

  • 90%+ of projects delivered on schedule

Companies that use PSI CRO AG

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

PSI CRO AG technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

PSI CRO AG partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • SanoficoreStrategic or Co-development Partner · 1 January 2026PSI CRO AG discussed site ID collaboration with Sanofi at SCOPE 2026, indicating a co-development partnership for clinical site identification and activation services.
  • University of MissouricoreStrategic or Co-development PartnerPSI CRO AG collaborates with the University of Missouri on radiopharmaceutical clinical research, leveraging academic expertise and patient populations for specialized oncology studies.
  • XcancercoreStrategic or Co-development PartnerPSI CRO AG partners with Xcancer in the field of radiopharmaceuticals, combining Xcancer's specialized oncology expertise with PSI CRO AG's global operational capabilities for clinical development.
  • ITM Isotope Technologies Munich SEcoreTechnology or IntegrationPSI CRO AG utilizes its VISIONAL platform in collaboration with ITM Isotope Technologies Munich SE for clinical and financial feasibility assessment in radiopharmaceutical studies, integrating PSI CRO AG's technology with ITM's isotope expertise.

Scale indicators4 records

Recent moves10 records

Expansion highlights5 records

PSI CRO AG competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

PSI CRO AG social profiles

Digital presence

PSI CRO AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PSI CRO AG leadership team

Management profile

Number of profiles

Profiles10 records

PSI CRO AG funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PSI CRO AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PSI CRO AG

What does PSI CRO AG do?

PSI CRO AG is a global full-service Contract Research Organization (CRO) that delivers pivotal Phase II–III clinical trials on time for pharmaceutical and biotech sponsors across eight therapeutic areas: oncology, gastroenterology, hematology, cell and gene therapy, neurology, infectious diseases, radiopharmaceuticals, and respiratory. Operations span 58 countries with 3,200+ professionals and 10,000+ investigator sites, supported by the proprietary INTELIA™ AI-powered technology platform suite (SYNETIC™, VISIONAL™, CLARITY™, CADENCE™, INSITE™, PACE™).

Is PSI CRO AG a public or private company?

PSI CRO AG is a private company. It is classified as management employee owned and is currently operating.

When was PSI CRO AG founded?

PSI CRO AG was founded in 1995. It employs 1,001 to 5,000 people.

Where is PSI CRO AG based?

PSI CRO AG is headquartered in Zug, Switzerland, in the Europe region.

How does PSI CRO AG make money?

One revenue line is on record: clinical Research Services.

Does PSI CRO AG have an API?

No public API is recorded for PSI CRO AG.

What industry is PSI CRO AG in?

PSI CRO AG's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAppian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial OperationsAppian and PSI CRO launched their first joint AI-powered process orchestration solution for clinical trial site selection. The solution automates site identification across therapeutic areas and geographies, integrating with PSI's systems and Appian's AI capabilities. The companies plan to extend AI-powered orchestration across the full clinical trial lifecycle.Stock TitanAppian, PSI CRO launch AI clinical trial site selectionAppian and PSI CRO launched a joint AI-powered solution to automate clinical trial site identification and selection. The solution integrates with PSI's systems and Appian's AI capabilities, aiming to improve efficiency and speed. The companies plan to extend AI-powered process orchestration across the clinical trial lifecycle.PR NewswireAppian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial OperationsAppian and PSI CRO launched their first joint AI-powered process orchestration solution for clinical trial site selection. The solution automates site identification across therapeutic areas and geographies, integrating with PSI's systems and Appian's AI capabilities. The companies plan to extend AI-powered orchestration across the full clinical trial lifecycle.MoomooAppian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial OperationsAppian and PSI CRO launched their first joint AI-powered process orchestration solution for clinical trial site selection. The solution automates site identification and selection across therapeutic areas and geographies, integrating with PSI's systems and Appian's AI capabilities. The companies plan to extend AI-powered orchestration across the clinical trial lifecycle to shorten studies and reduce costs.AktienAppian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial OperationsAppian and PSI CRO announced their first joint AI-powered process orchestration solution for clinical trial site selection. The solution automates site identification and selection across therapeutic areas, indications, and geographies, integrating with PSI's core systems and Appian's AI capabilities. It is the first step in a shared platform strategy for the full clinical trial lifecycle.AktienAppian und PSI CRO schließen strategische Partnerschaft zur Weiterentwicklung KI-gestützter klinischer StudienprozesseAppian and PSI CRO announced their first joint AI-powered solution for orchestrating clinical trial site selection, automating identification and selection across therapies, indications, and countries. The solution is the first step toward a scalable platform integrating automation, AI, and process orchestration for the entire clinical trial lifecycle.PR NewswireAppian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial OperationsAppian and PSI CRO launched their first joint AI-powered clinical trial site selection solution, automating site identification across therapeutic areas and geographies. The solution integrates with PSI's systems and Appian's AI capabilities, aiming to improve efficiency and speed. The companies plan to extend AI-powered process orchestration across the full clinical trial lifecycle.PR NewswireAppian und PSI CRO schließen strategische Partnerschaft zur Weiterentwicklung KI-gestützter klinischer StudienprozesseAppian and PSI CRO announced a joint AI-powered solution for orchestrating clinical trial site selection, automating the identification and selection of appropriate sites across therapies, indications, and countries. The solution integrates Appian's platform with PSI's systems to improve transparency and speed, and is the first step toward a broader platform strategy for the entire clinical trial lifecycle.Psi-CroThe Global CRO You Can TrustPSI CRO has been named a winner in the Overall respondent group category for the sixth consecutive year at the CRO Leadership Awards. The awards, presented by Life Sciences Leader and Clinical Leader based on ISR Reports research, recognize contract research organizations voted by sponsors to meet or exceed expectations.PR NewswireClarity and PSI kick off SAR-bisPSMA Phase IIIClarity Pharmaceuticals and PSI CRO AG have entered into an agreement and commenced work on Clarity's Phase III diagnostic trial CLARIFY for SAR-bisPSMA in prostate cancer patients. The non-randomised, open-label trial will enroll 383 participants to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET imaging for detecting prostate cancer in pelvic lymph nodes. Recruitment is expected to begin in late 2023, supported by positive FDA guidance on the program.